Vertex Pharmaceuticals (VRTX) stock in focus as company secures EU backing to expand label for its cystic fibrosis therapy ...

Vertex Pharmaceuticals (VRTX) has been one of the most searched-for stocks on Zacks.com lately. So, you might want to look at some of the facts that could shape the stock's performance in the near ...

Erste Group upgraded Vertex Pharmaceuticals (VRTX) to Buy from Hold. The firm expects the company to “develop positively in the coming quarters ...

Analysts have been eager to weigh in on the Healthcare sector with new ratings on Alphatec Holdings (ATEC – Research Report), Vertex ...

The pharma industry is delivering game-changing therapies with favorable regulatory support. Amid this backdrop, investors ...

Fintel reports that on February 12, 2025, Canaccord Genuity upgraded their outlook for Vertex Pharmaceuticals (NasdaqGS:VRTX) from Sell to Hold. Analyst Price Forecast Suggests 10.64% Upside As of ...

We sell different types of products and services to both investment professionals and individual investors. These products and services are usually sold through license agreements or subscriptions ...

Vertex Pharmaceuticals Incorporated, a biotechnology company, engages in developing and commercializing therapies for treating cystic fibrosis (CF). It markets TRIKAFTA/KAFTRIO for people with CF ...

Vertex Pharmaceuticals (NASDAQ:VRTX – Free Report) had its price target upped by Royal Bank of Canada from $407.00 to $408.00 ...

Cantor Fitzgerald issued their FY2025 EPS estimates for shares of Vertex Pharmaceuticals in a research note issued to ...

Vertex Pharmaceuticals (VRTX) has been one of the most searched-for stocks on Zacks.com lately. So, you might want to look at some of the facts that could shape the stock's performance in the near ...